Pharmasight
Ship · Medable

ICON and Medable reached 85% eConsent adoption across 1,200+ participants in a menopause study.

ICON (CRO) running a U.S. menopause studyShipMedableTotal Consent

The partners needed to drive consent adoption in a complex women's health trial of more than 1,200 participants. They used Medable's Total Consent with a site-first approach to eConsent. The page reports 85% eConsent adoption.

Medable is a digital clinical trial platform used by pharma sponsors for eCOA, eConsent and decentralized trial delivery

This sits in the Ship stage of the AI use-case lifecycle: Named examples from the vendors pharma teams use to get an AI system live inside a real, regulated production workflow — validation, CRM, safety and clinical systems of record.

Source

Published by Medable on its own site — read the original case study on medable.com ↗

More like this

Related use cases

  1. 01A top-10 pharma built three Phase III oncology studies in parallel across 30 countries on Medable's platform.A top-10 global pharmaceutical companyMedableShip
  2. 02A top-5 pharma scaled global vaccine mega-trials with Medable's eCOA and AI-assisted study build tools.A top-5 pharmaceutical companyMedableShip
  3. 03A top pharma ran a long-term follow-up obesity trial on Medable without an EDC and kept 97% of patients.A top pharmaceutical company running a decade-long global obesity studyMedableShip
  4. 04A biotech worried older participants would struggle with eCOA, and Medable support delivered over 90% adherence in its vaccine trial.A prominent biotech companyMedableShip
  5. 05Transforming Content Operations for 2x Faster Time to MarketUCBVeeva SystemsShip
  6. 06Astellas: Breaking Access Barriers with Veeva Compliant ChatAstellasVeeva SystemsShip